Rapid-acting Inhaled Insulin Powder (Afrezza) for Treating Diabetes

Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 1(Expected to be used by 0 to 20% of eligible patients)

Unfavorable coverage policies, product pricing up to 125% higher than that of competing rapid-acting injectable insulins, a boxed warning for patients with lung disease, and the end of “big pharma" marketing support (Sanofi S.A., Paris, France) appear to have greatly dampened diffusion of Afrezza® inhaled insulin (MannKind Corp., Westlake Village, CA, USA).

**Estimated Adoption Status:...